Quarles  

Wolf  

  New Frontiers in Phosphorus Homeostasis in CKD Flash slide/audio
(ASN Renal Week Official Symposium November, 2008)
Quarles: What role does FGF23 play in hereditary and acquired disorders of phosphate metabolism? What happens when there is too much FGF23? When there is too little? Where is FGF23 made? What are its target organs? How is FGF23 regulated? How do FGF23 and vitamin D interact? What are current controversies regarding FGF? Wolf: How do phosphorus, FGF23, and vitamin D change in the early stages of CKD? How are phosphorus and FGF23 linked to mortality in CKD? What do preliminary data show about FGF23 and progression? What is the effect of sevelamer on FGF23 levels?
(more...)


Thadhani  

Kestenbaum  

  Managing CKD-MBD through the Disease Continuum Flash slide/audio
(ASN Renal Week Official Symposium November, 2008)
Thadhani: Both 25D and 1,25D may be of benefit to CKD patients prior to dialysis. What evidence suggests that both may be important? What does uremia due to synthesis of cholecalciferol in the skin? How is conversion to 1,25D affected and why? How soon in the course of CKD are changes in 25D and 1,25D apparent? What do experimental studies show with regard to 25D vs. 1,25D in terms of causation/regression of LVH? Kestenbaum: When should one start a phosphate binder in predialysis CKD patients? At what stage is phosphate excretion affected and how? How does FGF23 affect phosphate excretion? Where is FGF23 made? Where does it act in the kidney? How are its actions similar / different from those of PTH? What is the evidence regarding phosphate and calcification?
(more...)


Qunibi  

Nolan  

Management of Hyperphosphatemia in Patients with ESRD: A New Direction for Treatment in 2008  (Medical Education Resources, Cancun, Mexico, January, 2008)
Qunibi: How do sevelamer and acetate compare in terms of phosphate control? In terms of grams of binder needed to achieve equivalent phosphate control? The explanation for reduced progression rate of vascular calcification in the RIND and DCOR studies has been lack of calcium-loading with sevelamer. To what extent is an alternative hypothesis, that of lowering of LDL- cholesterol, consistent with the data? What are data in animal models regarding vascular calcification in CKD and the effect of calcium-based phosphate binders? In the CARE-2 study (now available on-line at the AJKD website) progression of calcification was compared between calcium acetate plus atorvastatin and sevelamer plus atorvastatin (as needed to achieve equivalent LDL levels). What were the principal findings of CARE-2? Nolan: What did Treat-to-Goal, DCOR, RIND, DCOR Revisited, and CARE-2 show with respect to both calcification and mortality? How were the mortality results different from the calcification results? What are the DOPPS data with regard to phosphate binder use and mortality? What percentage of patients do the KDOQI guidelines recommend for non-calcium containing phosphate binders? What are the relative costs of sevelamer, calcium acetate, and calcium carbonate? (more...)



Bushinsky  

Block  

Llach  

Mehrotra  

Medical Crossfire: Managing Phosphorus in CKD -- The Challenge Remains  (ASN Renal Week Official Symposium, 2007)
Panel Discussion: What are the factors that promote vascular calcification in early CKD and in ESRD? How does vascular calcification affect prognosis? Should we screen for vascular calcification? If so, how? If yes, then how do we use this information? What should the target serum phosphate levels be as CKD progresses from stage 3 through 5? How good is the data suggesting lower phosphate targets? What are the various phosphate binder options available? Are they equally effective? Equally potent? Are there patient factors affecting choice of binder? To what extent should we control serum phosphate in predialysis patient? How should this be done? What are the key take-home points? (more...)



London  

Langman  

Ketteler  

Phosphate Binders in CKD: An Update on Treatment Outcomes and Future Directions  (ASN Renal Week Official Symposium, 2007)
Langman: What is the pathogenesis of mineral bone disorder in CKD? As GFR falls, at what point does serum Pi increase? What is the comparative efficacy of currently used Pi binders? What's the association between serum Pi levels and cardiovascular risk in ESRD, stage 2-4 CKD, and stage 2 CKD? What percent have coronary calcification at onset of dialysis? What were the conclusions of the DCOR and RIND studies in terms of coronary calcification and survival in patients using sevelamer vs. calcium-containing binders? What are the new data concerning sevelamer carbonate? Ketteler: What is fibroblast growth factor 23, and what is its role in phosphate excretion as GFR falls? How does extracellular phosphate affect vascular smooth muscle biology? What are the pathways for activating vascular smooth muscle transformation into osteoblast phenotypes? What does fetuin-A do? How does sevelamer affect fetuin-A levels? What is the role of matrix Gla protein and pyrophosphate in preventing calcification? (more...)


Updated: December 21, 2015 (Dec21)
Dec21 Ergocalciferol supplementation does not affect ESA dose in dialysis patients.
Dec14 Even more news on the new HDCN Facebook page!
Oct20 Vitamin D therapy may not contribute to kidney stones.
Feb16 Another study shows increased cardiovascular risk in women with high calcium intake.
Feb16 Vitamin D potency varies widely in nonprescription supplements.
Nov05 Randomized trial shows benefit for chelation therapy for heart disease.
Nov05 Cinacalcet for hyperparathyroidism trial results published in NEJM.
Nov05 Weight loss by bariatric surgery can lead to reduced bone density.
Nov01 DOPPS practice monitor updated in October 2012
Oct02 100K units of vitamin D per month does not reduce incidence of colds.
Sep07 CKD patients have reduced ability to prevent vascular calcification.
Aug16 DOPPS Practice Monitor website
Jul21 JASN RCT finds no benefits of 3 phosphorus binding drugs on vascular calcification in predialysis CKD..
Jul12 Ethanol consumption quickly slows elevated bone turnover rate; protects against osteoporosis in women.
Jul05 Fracture benefits of vitamin D in the elderly appear only at doses greater than 800 IU / day.
General Advances Emphasis
archive
Bone and Mineral Changes in Dialysis Patients (Dittrich) NANT 2009
Managing CKD-MBD through the Disease Continuum (Thadhani, Kestenbaum) ASN Renal Week 2008
Controlling Phosphorus in the Dialysis Population in 2008: How Are We Doing? (F. Finn) ASN Renal Week 2008
Phosphorus Homeostasis and Mortality Risk in the General, Non-Dialysis Population (N. Fole) ASN Renal Week 2008
CKD, Bone, and Aging: Differences Between Young and Old (J. Sherrard) ASN Renal Week 2008
Phosphorus Control and Vitamin D Therapy: Survival Benefit in CKD (W. Coyne) ASN Renal Week 2008
New Frontiers in Phosphorus Homeostasis in CKD (Quarles, Wolf) ASN Renal Week 2008
Morbidity and Mortality Data: Relationship to Bone and Mineral Metabolism (Coyne) ADC 2008
Controversy 1: Bisphosphonates in CKD:  They Are Safe and Effective (Ho) ADC 2008
Controversy 1: Bisphosphonates in CKD:  They Are Dangerous and Should Be Avoided (Molony) ADC 2008
Novel Approaches and Significance of Phosphate Management (Molony) ADC 2008
Demystifying Calcification in the CKD Patient (Andress) ADC 2008
Disorders of Calcium and Phosphorus Metabolism (Wolf) ASN Board Review 2008
Therapeutic Approaches with Calcimimetics and Active Vitamin D (Coyne) ADC 2008
Revisiting the K/DOQI Clinical Practice Guidelines for Bone Metabolism in CKD (Nolan) ADC 2008
Prevention of Renal Bone Disease (Finkelstein) ADC 2008
Nutritional Supplements and Active Vitamin D in CKD (Ho) ADC 2008
The CV-Bone-SHPT Link, A New Paradigm in CKD (Andress) ADC 2008
Vascular Calcification in Pre-ESRD (B. Langman) ASN Renal Week 2007
Do Calcimimetics Have a Role in Early Stage CKD? (A. Portale) ASN Renal Week 2007
Hereditary Hypophosphatemic Rickets with Hypercalciuria: Role of the Sodium-Phosphate Cotransporter (Ichikawa) ASN Renal Week 2007
Medical Crossfire: Managing Phosphorus in CKD -- The Challenge Remains (Llach, Mehrotra) ASN Renal Week 2007
Pre-ESRD and Mineral Metabolism (Martin, Moe) ASN Renal Week 2007
Vitamin D Deficiency, Arterial/Endothelial Dysfunction and Cardiovascular Disease (M. London) ASN Renal Week 2007
Vitamin D Deficiency and Immune Function (Bikle) ASN Renal Week 2007
Vitamin D and Cancer Prevention (F. Garland) ASN Renal Week 2007
Got D? Vitamin D in CKD: Is it Helpful? How Much? How Measured? (Levin) ASN Renal Week 2007
Phosphate Binders in CKD: An Update on Treatment Outcomes and Future Directions (London, Langman) ASN Renal Week 2007
Vitamin D Deficiency and Diabetes (Type 1 and Type 2) (Bouillon) ASN Renal Week 2007
Metabolic Bone Disease (R. Weisinger) ASN Renal Week 2007
The Impact of Declining GFR on Bone Metabolism (M. Moe) ASN Renal Week 2007
Vitamin D and Progression of Renal Disease: What are the Mechanisms? (J. Martin) ASN Renal Week 2007
The Growing Trend of Phosphate Additives: Its Impact on the Renal and Non-Renal Populations (Murphy-Gutekunst) ADC 2007
Bone Turnover and Infammatory Markers in Dialyzed Patients with Coronary Arterial Calicification (Sulowicz) ADC 2007
Phosphate Control by Drugs (W. Coyne) ADC 2007
Should PTH Ratios Be the Standard of Care? (C. Van Stone) ADC 2007
Vascular Calicification in Chronic Kidney Disease (Hayden) ADC 2007
Factors Involved in Vascular Calcification: Understanding the Role of Phosphotonins (FGF-23), Matrix Gla and Fetuin A (Andress) ADC 2007
Measuring Vascular Calcification (PWV, Spiral CT, EBCT,etc.) Demystifying the Role of Calcemic and Noncalcemic Vitamin D Analogues in Vascular Calcifcation (W. Coyne) ADC 2007
Calciphylaxis and the Emerging Role of Sodium Thiosulfate (Hayden) ADC 2007
Phosphate Control by Dialysis (G. Kerr) ADC 2007
Survival Predictability of Time-Varying Indicators of Bone Disease (Kalantar-Zadeh) ADC 2007
The Relationship Between Cardiovascular Disease and Renal Osteodystrophy in Chronic Kidney Disease (Andress) ADC 2007
Understanding Active Vitamin D (Dickey) ADC 2007
Practical Approaches to Management of Hyperphosphatemia (K. Kuhlmann) RRI 2007
Coronary Artery Calcifications - A Critical Assessment of Imaging Techniques (Lembcke) RRI 2007
A Kinetic Model of Calcium Mass Balance During Dialysis Therapy (Gotch) RRI 2007
Contemporary Diagnosis and Treatment of Vitamin D-Related Disorders ASBMR 2006
Clinical implications of bone biopsy ASN Renal Week 2006 (audio only)
Magnesium Balance: Hypomagnesemia and Hypermagnesemia (Coyne) ASN Board Review 2006
Low Bone Turnover Disease: Consequences, Prevalence, Detection and Treatment (Thomas L. Cantor, BA; Hassan Fehmi, MD; Gerard M. London, MD; Simon Waller, MD, MBBS, BSc) ADC 2006 (audio only)
Newer Approaches to Renal Osteodystrophy in Chronic Kidney Disease Patients (London, Sprague, Coyne, Goodman, Wolf) ADC 2006 (audio only)
Update on Vascular Calcification in Chronic Kidney Disease (CKD) Patients (Isaac Teitelbaum, MD; Robert Toto, MD; Dennis Andress, MD; Gerard M. London, MD) ADC 2006 (audio only)
An Expert Panel Debates Key Clinical Issues in Mineral Metabolism and Mortality in CKD (Medical Crossfire) (Coyne, Moe, Martin) ASN Renal Week 2005
Recent Advances in Regulation of Calcium, Magnesium and Phosphate Homeostasis and Metabolism (Murer, Konrad, Huang, Weinman) ASN Renal Week 2005 (audio only)
Stones and Bones (Coe, Kramer, Thakker) ASN Renal Week 2005 (audio only)
Controversies in Managing Hyperphosphatemia in CKD and ESRD (Young, Rosas, Goldfarb) ASN Renal Week 2005 (audio only)
Advances in the Treatment of Renal Osteodystrophy (Goodman, Sprague) ASN Renal Week 2005 (audio only)
Strategies for Reducing Parathyroid Hyperplasia, Fractures and the Need for Parathyroidectomy in Renal Disease (Fukagawa, Cunningham) ASN Renal Week 2005 (audio only)
Atherosclerosis and Vascular Calcification in CKD (Hruska, Vanholder, Himmelfarb) ASN Renal Week 2005 (audio only)
Active Vitamin D Therapeutic Options: Links to Cardiovascular Outcomes in the Management of CKD (Wolf, Llach) ASN Renal Week 2005 (audio only)
Managing Renal Osteodystrophy: Discussion of Interesting Cases (Sprague, Moe) ASN Renal Week 2005 (audio only)
Case Discussions: Disorders of Calcium Metabolism (Bushinsky, Andress) ASN Board Review 2005
The Role of Vitamin D in CKD (Slatopolsky, Sprague, Thadhani) ADC 2005 (audio only)
Tissue and Vascular Calcification: Clinical Overview and Detection (Raggi) ASN 2004
Coronary Artery Calcification: Scanning Methods and Clinical Results in the General Population (Rumberger)
Mineral and Metal Accumulation Without Changes in the "Usual Laboratory Suspects": How to Detect and Manage such Patients (Moe) ASN 2004
The Essential Role of Vitamin D in the Pathophysiology of CKD (Jones) ASN 2004
Mineral and Bone Treatment Options for the Stage 3 and 4 CKD Patient (Lindberg) ASN 2004
Calciphylaxis (Bleyer) ASN Renal Week 2004
Bones, Moans, and Groans: Skeletal Disorders in Chronic Kidney Disease Part 2 of 2. (Alleman) ANNA
Bones, Moans, and Groans: Skeletal Disorders in Chronic Kidney Disease Part 1 of 2. (Alleman) ANNA

Oral Phosphate Binders (Hutchison et al) Kidney Int May 2009
Latest findings in phosphate homeostasis (Prie et al) Kidney Int May 2009
Bone, Fat, and Body Composition: Evolving Concepts in the Pathogenesis of Osteoporosis (Rosen and Klibanski) Am J Med (May 2009)
Alternative milk beverages J Ren Nutr (Mar 2009)
The ubiquitous nature and elusive role of phosphorus and vascular calcification Am J Kidney Dis (Mar 2009)
Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure Kidney Int (Mar 2009)
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis Am J Kidney Dis (Feb 2009)
Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease Blood Purif (Feb 2009)
Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue Clin J Am Soc Nephrol (Jan 2009)
Spurious Hyperphosphatemia in Patients on Hemodialysis With Catheters (Schiller et al) Am J Kidney Dis (Sep 2008)
Oral estrogen therapy in postmenopausal women is associated with loss of kidney function Kidney Int - Aug - 08
Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics (Goodman WG et al) Kidney Int - Aug -08
Oral estrogen therapy in postmenopausal women is associated with loss of kidney function Kidney Int (Aug 2008)
Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics Kidney Int (Aug 2008)
A vitamin D nutritional cornucopia: new insights concerning the serum 25-hydroxyvitamin D status of the US population Am J Clin Nutr (Dec 2008)
The impact of systemic calcified atherosclerosis in patients with chronic kidney disease Adv Chronic Kidney Dis (Oct 2008)
Spurious hyperphosphatemia in patients on hemodialysis with catheters Am J Kidney Dis (Sep 2008)
Calcimimetics in chronic kidney disease: evidence, opportunities and challenges Kidney Int (Aug 2008)
Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med (Oct 2008)
Nonphosphate-binding effects of sevelamer -- are they of clinical relevance? Semin Dial (Oct 2008)
Oxalate in renal stone disease: the terminal metabolite that just won't go away NCPN (Jul 2008)
Urinalysis: core curriculum 2008 Am J Kidney Dis (Jun 2008)
Factors associated with osteonecrosis of the jaw among bisphosphonate users Am J Med (Jun 2008)
Adynamic bone in patients with chronic kidney disease Kidney Int (Jun 2008)
WNK kinases and renal sodium transport in health and disease: an integrated view Hypertens (Mar 2008)
A dietary alternative to phosphorus control J Ren Nutr (Mar 2008)
Mechanisms of vascular calcification in chronic kidney disease J Am Soc Nephrol (Feb 2008)
Metabolic acidosis inhibits soft tissue calcification in uremic rats Kidney Int (Feb 2008)
Battleground: chronic kidney disorders mineral and bone disease - calcium obsession, vitamin F, and binder confusion Clin J Am Soc Nephrol (Jan 2008)
Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient Hemodial Int (Jan 2008)
Towards the incidence of acute phosphate nephropathy (Markowitz et al) J Am Soc Nephrol (Dec 2007)
Genetics of hypercalciuric stone forming diseases (Devuyst et al) Kidney Int (Nov 2007)
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients (Suki et al) Kidney Int (Nov 2007)
Incidence and clinical spectrum of thiazide-associated hypercalcemia (Wemers et al) Am J Med (Oct 2007)
Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-(OH)2-D3 (Jones) Semin Dial (Aug 2007)
The role of magnesium binders in chronic kidney disease (Spiegel) Semin Dial (Aug 2007)
Hidden phosphorus: where do we go from here? (Lisa Murphy- Gutekunst) J Ren Nutr (Jul 2007)
Hidden Phosphorus: Where Do We Go From Here? (Murphy-Gutekunst L) J Ren Nutr (Jul 07)
Hypophosphatemia: clinical consequences and management (Brunelli et al) J Am Soc Nephrol (Jul 2007)
Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies (Drueke et al) Nephrol Dial Transplant (Jul 2007)
Bisphosphonates in the renal patient (Cunningham) Nephrol Dial Transplant (Jun 2007)
How fibroblast growth factor 23 works (Liu et al) J Am Soc Nephrol (Jun 2007)
Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients (Raggi et al) Hypertens (Jun 2007)
Calcific uremic arteriolopathy: advances in pathogenesis and treatment (Rogers et al.) Semin Dial (Apr 2008)
Hypomagnesemia in patients with type 2 diabetes CJASN 03-07
Metabolic bone disease in chronic kidney disease (Martin, Gonzalez) JASN (03-2007)
Metabolic bone disease in chronic kidney disease JASN 03-07
ACCF/AHA 2007 Clinical Expert Consensus Document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. Circulation (02-07)
Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. JASN (01-07)
Calcific uremic arteriolopathy: advances in pathogenesis and treatment Semin Dial 04-07
Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression JASN (01-2007)
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. (A. Levin et al) Kidney Int 01-07
KDOQI
K-DOQI Bone Guidelines
Reimbursement
Renagel Patient Assistance
Other Guidelines
ESRD 11 Bone med protocols
Topic Pages
Bone Disease
Hypercalcemia
Hypocalcemia
Hypermagnesemia
Hypomagnesemia
Cardiac